EDARBI CLD AZILSARTAN-CHLORTALIDONE

Description

EDARBI CLD® contains an angiotensin II receptor blocker (angiotensin II receptor blocker, ARB) and a thiazide-like diuretic. EDARBI CLD® is indicated for the treatment of moderate to severe hypertension, as it lowers blood pressure. EDARBI CLD® can be used as initial therapy in case the patient needs several drugs to achieve control of blood pressure.

There is evidence that the concomitant use of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers or aliskiren-containing products increases the risk of hypotension, hyperkalemia, and decreases renal function (including acute renal failure). Simultaneous blockade of the renin angiotensin aldosterone system through the combined use of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, or aliskiren-containing products is not recommended.

The choice of EDARBI CLD® as initial therapy for hypertension should be based on an evaluation of the potential benefits and risks, including whether the patient is likely to tolerate the initial dose of EDARBI CLD®.

Patients with moderate to severe hypertension are at relatively high risk for cardiovascular problems (eg, stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target value, and the gradual probability of reaching the target value with a combination product, such as EDARBI CLD®, compared to a monotherapy product, when deciding on initial therapy with EDARBI CLD®.

Data from an 8-week, active-controlled factorial trial provide estimates of the likelihood of achieving a target blood pressure with EDARBI CLD®, compared to monotherapy with azilsartan medoxomil or chlorthalidone.